AI Generated Image
LSD Just Passed Its Biggest Test Yet for Treating Depression
Gizmodo • • business
Key Points:
- Definium Therapeutics announced promising Phase III trial results for DT120, its proprietary LSD-based treatment, showing significant symptom reduction in major depression patients compared to placebo after a single dose.
- In the trial involving 149 participants, DT120 users experienced an 8.1-point greater drop in depression scores at six weeks, with 35% showing substantial response and 12% achieving remission, effects that persisted moderately through 12 weeks.
- Lead researcher John Sonnenberg highlighted DT120's potential as a rapid, durable, and fundamentally different treatment option for depression, addressing limitations of current therapies that often require chronic daily use.
- Definium plans to seek expedited FDA approval and breakthrough therapy designation for DT120, pending results from a second Phase III trial and external expert validation of the data.
- If approved, DT120 could represent a significant advancement in psychedelic medicine and depression treatment, offering hope for patients unresponsive to existing antidepressants.
